
    
      PRV-015-002b is a Phase 2b, randomized, double-blind, placebo-controlled, parallel-group
      study to evaluate the efficacy and safety of 3 dose regimens of PRV-015 in adult patients
      with NRCD who are on a GFD.

      Eligible subjects include male or female adults, 18 to 70 years of age, with a diagnosis of
      celiac disease and have followed a GFD for at least 12 consecutive months, yet continue to
      experience symptoms.

      Study drug (1 of the 3 doses of PRV-015 or placebo) will be administered in a double-blind
      fashion, followed by a safety follow-up period.
    
  